secwatch.observer — SEC 8-K summary
======================================

Issuer:     MeiraGTx Holdings plc (MGTX)
CIK:        0001735438
Form:       8-K
Filed at:   2024-10-15T23:59:59+00:00
Accession:  0001558370-24-013273
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MeiraGTx reports positive Phase 2 data for AAV-GAD in Parkinson's; 18-point UPDRS improvement in high-dose group
--------------------------------------------------------------------------------

- AAV-GAD met primary safety endpoint; no SAEs related to treatment in 14-patient bridging study.
- High-dose group showed 18-point average improvement in UPDRS Part 3 off-medication (p=0.03); sham and low-dose showed no significant change.
- PDQ-39 quality-of-life score improved by 8 points (p=0.02) in high-dose and 6 points (p=0.04) in low-dose groups.
- 100% of high-dose participants reported PDQ-39 improvement vs 60% low-dose and 25% sham.
- Company plans to advance AAV-GAD into Phase 3 trial globally; total of 58 patients treated across program with no related SAEs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1735438/000155837024013273/0001558370-24-013273-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1735438/000155837024013273/mgtx-20241015x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-013273

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer